Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes
Diabetology International · 2027-01 · 18 (1)
DOI: 10.1007/s13340-026-00940-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetology International, online erschienen am 31.10.2026. Verfasst von Hideyuki Okuma. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Nerima Hikarigaoka Hospital, 2-5-1 Hikarigaoka, Nerima-ku, Tokyo, 1790072 Japan. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Tirzepatide improves body weight and glycemic control in patients with type 2 diabetes, but factors associated with inter-individual differences after switching remain unclear. We examined whether baseline monocyte glucose-dependent insulinotropic polypeptide receptor (GIPR) mRNA expression was associated with changes in body weight and the fibrosis-4 (FIB-4) index after switching from glucagon-like peptide−1 receptor agonists (GLP-1RAs) to tirzepatide.
Methods
This single-center retrospective study included 90 patients with type 2 diabetes who had received a GLP-1RA for at least 6 months before switching. Baseline monocyte GIPR mRNA expression was measured by quantitative real-time polymerase chain reaction. Associations with percentage body-weight change and FIB-4 index change during the 6 months after tirzepatide initiation were assessed by correlation and multivariable regression. Exploratory ex vivo assays were performed to assess monocyte responses to native GIP.
Results
Higher baseline monocyte GIPR mRNA expression was associated with greater reductions in body weight and the FIB-4 index and remained significant in multivariable models. The association with the FIB-4 index remained significant after additional adjustment for percentage body-weight change at 6 months after tirzepatide initiation. GIPR mRNA expression was not associated with body-weight change during the preceding 6 months of GLP-1RA therapy. Native GIP suppressed lipopolysaccharide-induced interleukin-6 and tumor necrosis factor-alpha responses in monocytes.
Conclusions
Baseline monocyte GIPR mRNA expression was associated with body-weight and FIB-4 index reductions after switching to tirzepatide. It may represent an exploratory marker of clinical changes, but treatment specificity, causal GIPR-dependent mechanisms, and structural liver fibrosis regression were not established. Graphical abstract Summary of the study design and main finding. Baseline GIPR mRNA expression in peripheral blood monocytes was associated with reductions in body weight and the FIB-4 index after switching to tirzepatide in patients with type 2 diabetes. In exploratory ex vivo assays, native GIP suppressed LPS-induced inflammatory responses, supporting monocyte GIPR expression as a candidate exploratory marker requiring further validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, Nerima Hikarigaoka Hospital, 2-5-1 Hikarigaoka, Nerima-ku, Tokyo, 1790072 Japan.
ORCID-Profile: Hideyuki Okuma
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Okuma, H. (2027). Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes. Diabetology International, 18(1). https://doi.org/10.1007/s13340-026-00940-3
Vancouver
Okuma H. Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes. Diabetology International. 2027;18(1). doi:10.1007/s13340-026-00940-3
BibTeX
@article{Okuma2027,
author = {Okuma, Hideyuki},
title = {Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes},
journal = {Diabetology International},
year = {2027},
volume = {18},
number = {1},
doi = {10.1007/s13340-026-00940-3}
}
EUVIMED